Nuvation Bio (NYSE:NUVB – Get Free Report) and Immunocore (NASDAQ:IMCR – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.
Risk and Volatility
Nuvation Bio has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Nuvation Bio and Immunocore, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuvation Bio | 1 | 2 | 9 | 0 | 2.67 |
| Immunocore | 1 | 4 | 5 | 1 | 2.55 |
Nuvation Bio presently has a consensus target price of $13.22, indicating a potential upside of 182.77%. Immunocore has a consensus target price of $55.86, indicating a potential upside of 83.92%. Given Nuvation Bio’s stronger consensus rating and higher possible upside, equities analysts clearly believe Nuvation Bio is more favorable than Immunocore.
Profitability
This table compares Nuvation Bio and Immunocore’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuvation Bio | -88.18% | -46.59% | -22.01% |
| Immunocore | -4.20% | -4.54% | -1.66% |
Valuation & Earnings
This table compares Nuvation Bio and Immunocore”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuvation Bio | $169.90 million | 9.66 | -$204.63 million | ($0.44) | -10.63 |
| Immunocore | $430.77 million | 3.63 | -$35.51 million | ($0.37) | -82.08 |
Immunocore has higher revenue and earnings than Nuvation Bio. Immunocore is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Immunocore beats Nuvation Bio on 8 of the 15 factors compared between the two stocks.
About Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
About Immunocore
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
